What is Sava?
Sava is at the forefront of redefining personal health interaction through advanced biosensing technology. The company's innovative approach aims to provide painless, real-time, and affordable access to crucial bodily information, positioning itself as a leader in the health tech industry. This focus on accessible, in-depth health data positions Sava to address a critical need for proactive and informed healthcare.
How much funding has Sava raised?
Sava has raised a total of $27M across 2 funding rounds:
Angel/Seed
$8M
Series A
$19M
Angel/Seed (2024): $8M with participation from Balderton and EXOR
Series A (2025): $19M led by Exceptional Ventures, JamJar Investments, Balderton, True Capital, Italian Founders Fund, Norrsken Vc, and Athletico Ventures
Key Investors in Sava
Balderton
Balderton Capital is a prominent London-based venture capital firm specializing in early-stage, high-growth technology companies across Europe, often leading Seed and Series A rounds.
EXOR
Exor is a global investment holding company with a diversified portfolio across various sectors including automotive, financial services, and real estate, known for its medium to long-term investment strategy.
Exceptional Ventures
Exceptional Ventures appears to be associated with Saga Magazine, focusing on services and content for individuals over 50, including health, travel, and financial solutions.
What's next for Sava?
With this major strategic investment, Sava is poised for significant expansion and further development of its groundbreaking biosensing capabilities. The substantial capital infusion will likely fuel advancements in research and development, enhance manufacturing scalability, and broaden market penetration. This funding round signals strong investor confidence in Sava's vision to revolutionize how individuals engage with their health, suggesting a trajectory towards becoming a dominant player in the digital health and wellness landscape.
See full Sava company page
